Analyst Price Targets — PHAT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 27, 2026 8:55 am | Jenna Davidner | Barclays | $18.00 | $10.58 | TheFly | Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays |
| February 26, 2026 5:51 pm | Annabel Samimy | Stifel Nicolaus | $28.00 | $13.62 | StreetInsider | Stifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
| December 11, 2025 9:10 pm | Martin Auster | Raymond James | $28.00 | $14.56 | TheFly | Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 8, 2025 9:27 pm | Jenna Davidner | Barclays | $16.00 | $14.90 | TheFly | Phathom Pharmaceuticals initiated with an Equal Weight at Barclays |
| October 31, 2025 1:26 pm | Chase Knickerbocker | Craig-Hallum | $22.00 | $13.76 | TheFly | Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum |
| October 31, 2025 10:10 am | — | H.C. Wainwright | $26.00 | $13.31 | TheFly | Phathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright |
| October 30, 2025 4:03 pm | Yatin Suneja | Guggenheim | $20.00 | $13.31 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $20 at Guggenheim |
| March 7, 2025 2:16 pm | — | Guggenheim | $18.00 | $5.06 | TheFly | Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim |
| August 8, 2024 4:17 pm | Paul Choi | Goldman Sachs | $12.00 | $11.75 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs |
| July 19, 2024 10:02 am | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
Latest News for PHAT
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal…
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in…
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHAT.
U.S. House Trading
No House trades found for PHAT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.